agnosis and treatment. Am J Clin Dermatol. 2009;10:365-81.
24. Ooi ET, Tidman MJ. Improving the management of seborrhoeic dermatitis. Practitioner .2014;258:23-6, 3.
25. Helfrich YR, Maier LE, Cui Y, et al. Clinical, histologic, and molecular analysis of differences between eythematotelangiectatic rosacea and telangiectatic photoaging. JAMA Dermatol. 2015;151:825-36.
26. Sonthalia S, Arora R, Chhabra N, et al. Favre-Racouchot syndrome. Ind Dermatol Online J. 2014;5:S128-9.
27. Barankin B, Guenther L. Rosacea and atopic dermatitis. Two common oculocutaneous disorders. Can Fam Physician. 2002;48:721-4.
28. Hartman-Adams H, Banvard C , Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014;90:229-35.
29. Datta I, Casanas B, Vincent AL, et al. The red face: Erysipelas versus, parvovirus B19, SLE, and rosacea. Asian Biomedicine. 2009;3:681-8.
30. Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:465-71.
31. Webster G, Schaller M, Tan J, et al. Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis. J Dermatol Treat. 2017;28:469-74.
32. Schaller M, Dirschka T, Kemeny L, et al. Superior efficacy with ivermectin 1% cream compared to metronidazole 0.75% cream contributes to a better quality of life in patients with severe papulopustular rosacea: A subanalysis of the randomized, investigator-blinded ATTRACT study. Dermatol Ther (Heidelb). 2016;6:427-36.
33. Gold LS, Papp K, Lynde C, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: A randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16:909-16.
34. Hofmann MA, Kokolakis G. A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea. J Cosm Laser Ther. 2017;19:222-4.
35. Nestor MS. Combination therapy in clinical and cosmetic dermatology: the marriage of device and drug. J Drugs Dermatol. 2004;3:S4-11.
24. Ooi ET, Tidman MJ. Improving the management of seborrhoeic dermatitis. Practitioner .2014;258:23-6, 3.
25. Helfrich YR, Maier LE, Cui Y, et al. Clinical, histologic, and molecular analysis of differences between eythematotelangiectatic rosacea and telangiectatic photoaging. JAMA Dermatol. 2015;151:825-36.
26. Sonthalia S, Arora R, Chhabra N, et al. Favre-Racouchot syndrome. Ind Dermatol Online J. 2014;5:S128-9.
27. Barankin B, Guenther L. Rosacea and atopic dermatitis. Two common oculocutaneous disorders. Can Fam Physician. 2002;48:721-4.
28. Hartman-Adams H, Banvard C , Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014;90:229-35.
29. Datta I, Casanas B, Vincent AL, et al. The red face: Erysipelas versus, parvovirus B19, SLE, and rosacea. Asian Biomedicine. 2009;3:681-8.
30. Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:465-71.
31. Webster G, Schaller M, Tan J, et al. Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis. J Dermatol Treat. 2017;28:469-74.
32. Schaller M, Dirschka T, Kemeny L, et al. Superior efficacy with ivermectin 1% cream compared to metronidazole 0.75% cream contributes to a better quality of life in patients with severe papulopustular rosacea: A subanalysis of the randomized, investigator-blinded ATTRACT study. Dermatol Ther (Heidelb). 2016;6:427-36.
33. Gold LS, Papp K, Lynde C, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: A randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16:909-16.
34. Hofmann MA, Kokolakis G. A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea. J Cosm Laser Ther. 2017;19:222-4.
35. Nestor MS. Combination therapy in clinical and cosmetic dermatology: the marriage of device and drug. J Drugs Dermatol. 2004;3:S4-11.
AUTHOR CORRESPONDENCE
Sandra Marchese Johnson MD FAAD drsandy@johnsondermatology.com
